Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

[The Involvement of Cardiomyocyte-Specific Transcription Factors Meis in Adipocyte Differentiation].

Greco A., Vaipan DV., Tkachuk VA., Penkov DN.

Animal Study on Cardiovascular Disease, published in Mol Biol (Mosk) (2019) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mol Biol (Mosk) (2019)
Country
Russia (Federation)
Reported sample size
—
Source database
PubMed
PMID
31184615
DOI
10.1134/S0026898419030078

Abstract (original English)

Homeodomain transcription factors play a significant role in adipocyte differentiation. The role of Pbx1 and Prep1, proteins of the TALE family (the three amino acid loop extension), was previously established in adipocyte differentiation of mesenchymal stromal cells and 3T3-L1 cell line. In this study, with the use of RNA interference technology we show that another transcription factor from the same family, Meis1, which is a core protein of mature cardiomyocytes, represses adipogenesis to a greater degree than its paralog Meis2. A number of Meis target genes, markers of adipocytes, are identified. This may indicate the transcriptional mechanism of the effect of Meis1 on the adipocyte differentiation of mouse preadipocytes.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AdipocytesAnimalsCell DifferentiationHomeodomain ProteinsMiceMyeloid Ecotropic Viral Integration Site 1 ProteinMyocytes, CardiacStem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research